Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene linked to risk of late-onset Alzheimer's:

This article was originally published in Clinica

Executive Summary

An international team of researchers has found an association between the CST3 gene and late-onset Alzheimer's disease. The researchers, based in Germany, Italy, Switzerland and the US, studied 517 Alzheimer's patients and 390 control subjects. They found that individuals who were over the age of 75 and homozygous for the CST3 gene, which encodes the endogenous proteinase inhibitor, cystatin C, were nearly nine times as likely to develop Alzheimer's disease as heterozygous individuals. Reporting their findings in the November issue of Archives of Neurology, they conclude that CST3 is a susceptibility gene for late-onset Alzheimer's disease, especially in patients aged over 75.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT075240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel